Annals of Surgical Oncology

, Volume 16, Issue 1, pp 128–132 | Cite as

Prognostic Impact of Satellite-Lymphovascular Space Involvement in Early-Stage Cervical Cancer

  • Daniel HerrEmail author
  • Jochem König
  • Volker Heilmann
  • Karin Koretz
  • Rolf Kreienberg
  • Christian Kurzeder
Gynecologic Oncology


Currently the prognostic value of lymphovascular space involvement (LVSI) in patients with cervical cancer is unclear. We evaluated the prognostic impact of different categories of LVSI on overall survival (OAS) and disease-free survival (DFS) in a Middle-European population of women with surgically staged, early cervical cancer. The records of 281 women with clinically and histologically diagnosed early cervical cancer undergoing primary surgical treatment at the University of Ulm School of Medicine between 1992 and 2006 were retrospectively reviewed. LVSI as determined by hematoxylin–eosin staining was topographically categorized as conjoined-LVSI and satellite-LVSI. The effect of LVSI, tumor stage, lymph node metastases, and histology on OAS and DFS was assessed by Cox regression analyses. Tumor size and nodal status could be confirmed as significant prognostic factors for OAS and DFS in early-stage cervical cancer. While no significant effect of LVSI in general (satellite-LVSI or conjoined-LVSI) on OAS and DFS was calculated, the presence of satellite-LVSI was associated with significant decreased rates of both, OAS and DFS. We propose satellite-LVSI as new risk factor for patients with early-stage cervical cancer, in order to better identify the patients urgently needing adjuvant therapy.


Cervical Cancer Nodal Status Histological Subtype Prognostic Impact Significant Prognostic Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350(9077):535–40.CrossRefPubMedGoogle Scholar
  2. 2.
    Creasman WT, Kohler MF. Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? Gynecol Oncol. 2004;92(2):525–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Kenter GG, Ansink AC, Heintz AP, Delemarre J, Aartsen EJ, Hart AA. Low stage invasive carcinoma of the uterine cervix stage I-IIA morphological prognostic factors. Eur J Surg Oncol. 1988;14(2):187–92.PubMedGoogle Scholar
  4. 4.
    Atasii T, Aksu MF, Cetinkaya MB. Prognostic factors that affect survival after the treatment of early stage cervical carcinoma. Int Surg. 2000;85(2):147–51.PubMedGoogle Scholar
  5. 5.
    Burghardt E, Baltzer J, Tulusan AH, Haas J. Results of surgical treatment of 1028 cervical cancers studied with volumetry. Cancer. 1992;70(3):648–55.CrossRefPubMedGoogle Scholar
  6. 6.
    Kim SM, Choi HS, Byun JS. Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection. Int J Gynecol Cancer. 2000;10(4):305–12.CrossRefPubMedGoogle Scholar
  7. 7.
    Trattner M, Graf AH, Lax S, Forstner R, Dandachi N, Haas J, et al. Prognostic factors in surgically treated stage ib-iib cervical carcinomas with special emphasis on the importance of tumor volume. Gynecol Oncol. 2001;82(1):11–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Tsai CS, Lai CH, Wang CC, Chang JT, Chang TC, Tseng CJ, et al. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy. Gynecol Oncol. 1999;75(3):328–33.CrossRefPubMedGoogle Scholar
  9. 9.
    Dawlatly B, Lavie O, Lopes A. Transvaginal evisceration of small bowel after radical hysterectomy and pelvic lymphadenectomy. Gynecol Oncol. 1999;73(1):165–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Shingleton HM, Gore H, Bradley DH, Soong SJ. Adenocarcinoma of the cervix I Clinical evaluation and pathologic features. Am J Obstet Gynecol. 1981;139(7):799–814.CrossRefPubMedGoogle Scholar
  11. 11.
    Schwartz SM, Weiss NS. Increased incidence of adenocarcinoma of the cervix in young women in the United States. Am J Epidemiol. 1986;124(6):1045–7.PubMedGoogle Scholar
  12. 12.
    Boon ME, de Graaff Guilloud JC, Kok LP, Olthof PM, van Erp EJ. Efficacy of screening for cervical squamous and adenocarcinoma The Dutch experience. Cancer. 1987;59(4):862–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Leminen A, Paavonen J, Forss M, Wahlstrom T, Vesterinen E. Adenocarcinoma of the uterine cervix. Cancer. 1990;65(1):53–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Hopkins MP, Morley GW. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol. 1991;77(6):912–7.PubMedGoogle Scholar
  15. 15.
    Miller BE, Flax SD, Arheart K, Photopulos G. The presentation of adenocarcinoma of the uterine cervix. Cancer. 1993;72(4):1281–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol. 1995;59(1):38–44.CrossRefPubMedGoogle Scholar
  17. 17.
    Samlal RA, van der Velden J, Ten Kate FJ, Schilthuis MS, Hart AA, Lammes FB. Surgical pathologic factors that predict recurrence in stage IB and IIA cervical carcinoma patients with negative pelvic lymph nodes. Cancer. 1997;80(7):1234–40.CrossRefPubMedGoogle Scholar
  18. 18.
    Anton-Culver H, Bloss JD, Bringman D, Lee-Feldstein A, DiSaia P, Manetta A. Comparison of adenocarcinoma and squamous cell carcinoma of the uterine cervix: a population-based epidemiologic study. Am J Obstet Gynecol. 1992;166(5):1507–14.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  • Daniel Herr
    • 1
    Email author
  • Jochem König
    • 2
  • Volker Heilmann
    • 1
  • Karin Koretz
    • 3
  • Rolf Kreienberg
    • 1
  • Christian Kurzeder
    • 1
  1. 1.Department of Obstetrics and GynecologyUlm University Medical CenterUlmGermany
  2. 2.Institute for Medical Biostatistics, Epidemiology and InformaticsJohannes Gutenberg University MainzMainzGermany
  3. 3.Department of PathologyUlm University Medical CenterUlmGermany

Personalised recommendations